ProQR Therapeutics (NASDAQ:PRQR) Receives $8.83 Average PT from Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has been assigned an average recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.83.

A number of research firms have weighed in on PRQR. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Oppenheimer started coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target for the company.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $2.40 on Friday. The firm has a market cap of $196.03 million, a PE ratio of -7.50 and a beta of 0.26. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The business has a 50-day moving average price of $2.69 and a 200 day moving average price of $2.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $4.22 million during the quarter, compared to analysts’ expectations of $4.75 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. On average, sell-side analysts expect that ProQR Therapeutics will post -0.31 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ballentine Partners LLC purchased a new stake in ProQR Therapeutics in the 4th quarter valued at $61,000. OneDigital Investment Advisors LLC grew its holdings in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. Raymond James Financial Inc. purchased a new position in ProQR Therapeutics during the fourth quarter worth about $260,000. Finally, M&T Bank Corp purchased a new position in ProQR Therapeutics during the fourth quarter worth about $330,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).